Table 3.
TEAEs, SAEs, and laboratory abnormalities across all cohorts
| TEAE of any grade ≥15%, n (%) | Total (N = 114) |
|---|---|
| Fatigue | 65 (57·0) |
| Nausea | 55 (48·2) |
| Diarrhoea | 52 (45·6) |
| Constipation | 30 (26·3) |
| Decreased appetite | 28 (24·6) |
| Cough | 27 (23·7) |
| Pyrexia | 27 (23·7) |
| Vomiting | 25 (21·9) |
| Anaemia | 21 (18·4) |
| Headache | 21 (18·4) |
| Dizziness | 20 (17·5) |
| Dyspepsia | 20 (17·5) |
| ALT increased | 19 (16·7) |
| Dyspnoea | 18 (15·8) |
| Upper respiratory tract infection | 18 (15·8) |
| SAE of any grade ≥2% | |
| Dyspnoea | 5 (4·4) |
| Acute kidney injury | 4 (3·5) |
| Anaemia | 3 (2·6) |
| Febrile neutropenia | 3 (2·6) |
| Pneumonia | 3 (2·6) |
| Laboratory abnormalities of any grade ≥20%: serum chemistry | |
| Creatinine increased | 66 (57·9) |
| ALT increased | 50 (43·9) |
| AST increased | 41 (36·0) |
| Hyperglycaemia | 37 (32·5) |
| Alkaline phosphatase increased | 34 (29·8) |
| Hypoalbuminaemia | 30 (26·3) |
| Total bilirubin increased | 30 (26·3) |
| Hyponatraemia | 28 (24·6) |
| Indirect blood bilirubin increased | 23 (20·2) |
| Laboratory abnormalities of any grade ≥20%: haematology | |
| Anaemia | 42 (36·8) |
| Neutropenia | 35 (30·7) |
| Lymphocytes decreased | 34 (29·8) |
| Leucocytes decreased | 33 (28·9) |
SAE, serious adverse event; TEAE, treatment‐emergent adverse event.